FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809762932> ?p ?o ?g. }

• W2809762932 endingPage "1644" @default.
• W2809762932 startingPage "1630" @default.
• W2809762932 abstract "Several immunohistochemistry (IHC) assays have been developed to assess tumor programmed death-ligand 1 (PD-L1) expression levels in patients who are candidates for programmed death-1 (PD-1)/PD-L1 inhibitor therapy. The PD-L1 IHC 28-8 pharmDx kit is FDA-approved as a complementary diagnostic and CE-marked as an in vitro diagnostic device for nivolumab therapy in melanoma and specific lung cancer subtypes (and for squamous cell carcinoma of the head and neck/urothelial carcinoma in Europe only). Kit availability is limited outside the United States, and its use requires the Dako Autostainer Link 48 platform, which is unavailable in many laboratories. Validated laboratory-developed tests based on 28-8 concentrated antibody outside the kit are needed. This study compared the results from PD-L1 expression level analysis across four immunohistochemistry platforms (Dako Autostainer Link 48, Dako Omnis, Leica Bond-III, and Ventana BenchMark ULTRA) with the 28-8 pharmDx kit in lung cancer (multiple histologies), melanoma, and head and neck cancer (multiple histologies). Samples were prepared per protocol for each platform and stained using PD-L1 IHC 28-8 pharmDx kit on Dako Autostainer Link 48, and per protocol for each platform. The control samples (tonsil and placenta tissue; cell lines with prespecified PD-L1 expression levels) were tested to evaluate the specificity and the sensitivity of test assays. An agreement level of 0.90 with the pharmDx kit was set for each platform. Inter- and intra-assay reliability were assessed. Evaluable samples were lung cancer = 29; melanoma = 31; head and neck cancer = 30. Mean agreement was calculated for PD-L1 expression levels of ≥1%, ≥5%, ≥10%, and ≥50%. Mean overall agreement for all indications was 0.87–0.99. Inter- and intra-assay of scoring/classification repeatability was 100%. Analysis of PD-L1 expression levels using laboratory-developed immunohistochemistry assays with 28-8 antibody may be permissible if the platform is validated using reference samples with defined expression levels." @default.
• W2809762932 created "2018-07-10" @default.
• W2809762932 creator A5011262316 @default.
• W2809762932 creator A5025677826 @default.
• W2809762932 creator A5028984477 @default.
• W2809762932 creator A5040577529 @default.
• W2809762932 creator A5044135081 @default.
• W2809762932 creator A5073094568 @default.
• W2809762932 creator A5086331591 @default.
• W2809762932 creator A5086661479 @default.
• W2809762932 creator A5087867870 @default.
• W2809762932 date "2018-01-01" @default.
• W2809762932 modified "2023-10-01" @default.
• W2809762932 title "Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms" @default.
• W2809762932 cites W1277869758 @default.
• W2809762932 cites W1568317937 @default.
• W2809762932 cites W1881020575 @default.
• W2809762932 cites W1978857579 @default.
• W2809762932 cites W1990779902 @default.
• W2809762932 cites W1994993231 @default.
• W2809762932 cites W2037972262 @default.
• W2809762932 cites W2040793402 @default.
• W2809762932 cites W2057893793 @default.
• W2809762932 cites W2071069178 @default.
• W2809762932 cites W2085768658 @default.
• W2809762932 cites W2086509569 @default.
• W2809762932 cites W2095614702 @default.
• W2809762932 cites W2097855813 @default.
• W2809762932 cites W2104347254 @default.
• W2809762932 cites W2122495232 @default.
• W2809762932 cites W2136859769 @default.
• W2809762932 cites W2156353875 @default.
• W2809762932 cites W2164001237 @default.
• W2809762932 cites W2181211402 @default.
• W2809762932 cites W2194796823 @default.
• W2809762932 cites W2398309632 @default.
• W2809762932 cites W2401835169 @default.
• W2809762932 cites W2467854262 @default.
• W2809762932 cites W2475667023 @default.
• W2809762932 cites W2509467148 @default.
• W2809762932 cites W2514478103 @default.
• W2809762932 cites W2521991465 @default.
• W2809762932 cites W2523428626 @default.
• W2809762932 cites W2523528921 @default.
• W2809762932 cites W2527905628 @default.
• W2809762932 cites W2554107370 @default.
• W2809762932 cites W2557730509 @default.
• W2809762932 cites W2569413005 @default.
• W2809762932 cites W2594102731 @default.
• W2809762932 cites W2605157312 @default.
• W2809762932 cites W2616943335 @default.
• W2809762932 cites W2635951006 @default.
• W2809762932 cites W2725050414 @default.
• W2809762932 cites W2740672372 @default.
• W2809762932 cites W2743893196 @default.
• W2809762932 cites W2748246139 @default.
• W2809762932 cites W2752031457 @default.
• W2809762932 cites W2755581089 @default.
• W2809762932 cites W2765696340 @default.
• W2809762932 cites W2770799637 @default.
• W2809762932 cites W2783338623 @default.
• W2809762932 cites W2786665544 @default.
• W2809762932 cites W2794076689 @default.
• W2809762932 cites W2891791187 @default.
• W2809762932 cites W2892169881 @default.
• W2809762932 cites W4230195560 @default.
• W2809762932 doi "https://doi.org/10.1038/s41379-018-0071-1" @default.
• W2809762932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29946185" @default.
• W2809762932 hasPublicationYear "2018" @default.
• W2809762932 type Work @default.
• W2809762932 sameAs 2809762932 @default.
• W2809762932 citedByCount "30" @default.
• W2809762932 countsByYear W28097629322018 @default.
• W2809762932 countsByYear W28097629322019 @default.
• W2809762932 countsByYear W28097629322020 @default.
• W2809762932 countsByYear W28097629322021 @default.
• W2809762932 countsByYear W28097629322022 @default.
• W2809762932 countsByYear W28097629322023 @default.
• W2809762932 crossrefType "journal-article" @default.
• W2809762932 hasAuthorship W2809762932A5011262316 @default.
• W2809762932 hasAuthorship W2809762932A5025677826 @default.
• W2809762932 hasAuthorship W2809762932A5028984477 @default.
• W2809762932 hasAuthorship W2809762932A5040577529 @default.
• W2809762932 hasAuthorship W2809762932A5044135081 @default.
• W2809762932 hasAuthorship W2809762932A5073094568 @default.
• W2809762932 hasAuthorship W2809762932A5086331591 @default.
• W2809762932 hasAuthorship W2809762932A5086661479 @default.
• W2809762932 hasAuthorship W2809762932A5087867870 @default.
• W2809762932 hasBestOaLocation W28097629321 @default.
• W2809762932 hasConcept C121608353 @default.
• W2809762932 hasConcept C126322002 @default.
• W2809762932 hasConcept C142724271 @default.
• W2809762932 hasConcept C143998085 @default.
• W2809762932 hasConcept C204232928 @default.
• W2809762932 hasConcept C2776256026 @default.
• W2809762932 hasConcept C2776530083 @default.
• W2809762932 hasConcept C2776833033 @default.
• W2809762932 hasConcept C2777701055 @default.

• next